Today, September 29th, marks World Heart Day. A day established by the World Heart Federation (WFH) that’s dedicated to help raise awareness around cardiovascular disease around the globe each year.

With a lot of new guidelines being published and updated, we’ve taken the courtesy of compiling all of the new cardiovascular disease guidelines, therapies and innovations that have been introduced since the last World Heart Day in 2021.

HEART FAILURE

American College of Cardiology (ACC),
American Heart Association (AHA), & Heart Failure Society of America (HFSA)

Published April 1, 2022

One of the most significant guideline updates to publish since the last World Heart Day. New recommendations are found for medications such as the SGLT2s, as well as more established medicines like Entresto. While the full guideline is quite lengthy, the Heart Failure Pocket Guide is available at no cost.

CHEST PAIN

American College of Cardiology (ACC), American Heart Association (AHA),
American College of Chest Physicians (CHEST), American Society of Echocardiography (ASECHO),
&Society of Cardiovascular Computed Tomography (SCCT))

Published October 28, 2021

The Chest Pain guideline haven’t witnessed a major update in roughly a decade. This guideline covers everything you need to know and it’s all included in Chest Pain Pocket Guide.

Other Additional Guidelines:

CAMZYOS (BRISTOL MYERS SQUIBB)

One of the most highly anticipated approvals in the cardiology space, BMS’ Camzyos gives hope to all patients dealing with HCM.

JARDIANCE (BOEHRINGER INGELHEIM / ELI LILLY)

While the medication itself is not new, the indication for heart failure patients is. As previously noted, the Heart Failure guidelines were updated to include recommendations for SGLT2s, including Jardiance

Other Additional Medications:

  • Xarelto (Janssen) Treatment of venous thromboembolism (VTE, or blood clots) and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have undergone the Fontan procedure.
  • Leqvio (Novartis) As an adjunct to statins for further reduction of LDL cholesterol levels.
  • Enjaymo (Sanofi) To decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease (CAD).
  • Norliqva (CMP Pharma, Inc.) For Hypertension and Coronary Artery Disease.
  • Camzyos (Bristol Myers Squibb) To improve functional capacity and symptoms in adults with symptomatic New York Heart Association (NYHA) class II to III obstructive hypertrophic cardiomyopathy (oHCM).
  • Tyvaso DPI (United Therapeutics) Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
  • Amvuttra (Alnylam Pharmaceuticals) Treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.

What’s on the horizon for october 2022 Through september 2023

Some of the upcoming cardiology guideline updates we’re very excited about, and expecting between now and the next World Heart Day 2023.

  • American College of Cardiology (ACC) & American Heart Association (AHA)
    • Aortic Disease
    • Chronic Coronary Disease
    • Peripheral Arterial Disease Update
    • Atrial Fibrillation Update
    • Hypertrophic Cardiomyopathy Rapid Update

This list is not exhaustive, but does give you an idea of some of the exciting new updates in development.

Copyright © 2022 Guideline Central, All rights reserved.